TNXP: Raymond James Initiates
Raymond James initiates coverage on Tonix Pharmaceuticals with a Strong Buy rating and $26 price target
Raymond James analyst Tiago Fauth initiates coverage on Tonix Pharmaceuticals (NASDAQ: TNXP ) with a Strong Buy rating and announces Price Target of $26.